Patents by Inventor Michael R. Erdos

Michael R. Erdos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Oligonucleotide analogues targeting human LMNA
    Patent number: 11802283
    Abstract: Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: October 31, 2023
    Assignees: Sarepta Therapeutics, Inc., The United States of America, as rep. by the Secretary, Dept. of Health and Human Services, The Progeria Research Foundation
    Inventors: Michael R. Erdos, Francis S. Collins, Kan Cao, Ryszard Kole, Richard Keith Bestwick, Leslie B. Gordon
  • OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA
    Publication number: 20210010001
    Abstract: Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Application
    Filed: September 17, 2020
    Publication date: January 14, 2021
    Applicants: Sarepta Therapeutics, Inc., The Progeria Research Foundation, THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, University of Maryland, The Progeria Research Foundation
    Inventors: Michael R. Erdos, Francis S. Collins, Kan Cao, Ryszard Kole, Richard Keith Bestwick, Leslie B. Gordon
  • Oligonucleotide analogues targeting human LMNA
    Patent number: 10822608
    Abstract: Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: November 3, 2020
    Assignees: Sarepta Therapeutics, Inc., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, University of Maryland, The Progeria Research Foundation
    Inventors: Michael R. Erdos, Francis S. Collins, Kan Cao, Ryszard Kole, Richard Keith Bestwick, Leslie B. Gordon
  • Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
    Patent number: 10398721
    Abstract: Provided are methods of treatment in subjects having progeroid diseases and related conditions which rely upon LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: September 3, 2019
    Assignees: SAREPTA THERAPEUTICS, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, UNIVERSITY OF MARYLAND, PROGERIA RESEARCH FOUNDATION, INC.
    Inventors: Ryszard Kole, Francis S. Collins, Michael R. Erdos, Kan Cao, Leslie B. Gordon
  • OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA
    Publication number: 20190127735
    Abstract: Provided are LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Application
    Filed: April 28, 2017
    Publication date: May 2, 2019
    Applicants: Sarepta Therapeutics, Inc., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES, UNIVERSITY OF MARYLAND
    Inventors: Michael R. Erdos, Francis S. Collins, Kan Cao, Ryszard Kole, Richard Keith Bestwick, Leslie B. Gordon
  • METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA
    Publication number: 20180271893
    Abstract: Provided are methods of treatment in subjects having progeroid diseases and related conditions which rely upon LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Application
    Filed: October 6, 2017
    Publication date: September 27, 2018
    Inventors: RYSZARD KOLE, Francis S. Collins, Michael R. Erdos, Kan Cao
  • Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
    Patent number: 9833468
    Abstract: Provided are methods of treatment in subjects having progeroid diseases and related conditions which rely upon LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Grant
    Filed: March 29, 2016
    Date of Patent: December 5, 2017
    Assignees: Sarepta Therapeutics, Inc., The United States of America, as represneted by the Secretary, Dept. of Health and Human Services, University of Maryland
    Inventors: Ryszard Kole, Francis S. Collins, Michael R. Erdos, Kan Cao
  • METHODS FOR TREATING PROGEROID LAMINOPATHIES USING OLIGONUCLEOTIDE ANALOGUES TARGETING HUMAN LMNA
    Publication number: 20170051278
    Abstract: Provided are methods of treatment in subjects having progeroid diseases and related conditions which rely upon LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Application
    Filed: March 29, 2016
    Publication date: February 23, 2017
    Inventors: Ryszard Kole, Francis S. Collins, Michael R. Erdos, Kan Cao
  • Methods for treating progeroid laminopathies using oligonucleotide analogues targeting human LMNA
    Patent number: 9326992
    Abstract: Provided are methods of treatment in subjects having progeroid diseases and related conditions which rely upon LMNA-targeted antisense oligonucleotides for reducing expression of one or more aberrantly spliced LMNA mRNA isoforms that encode progerin.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: May 3, 2016
    Assignees: Sarepta Therapeutics, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Maryland
    Inventors: Ryszard Kole, Francis S. Collins, Michael R. Erdos, Kan Cao